Idiopathic Pulmonary Fibrosis (IPF) is a chronic lung disease that develops when the lung tissue becomes scared or fibrotic over time. The scarring progresses differently in everyone, as some people’s disease stays the same for years, and in others, the condition can worsen rapidly.
Though the cause for this is relatively unknown, the risk for IPF is higher amongst smokers, or have a family history of IPF. The risk also increases with age, most often impacting people over age 50.
Risk factors of IPF include pulmonary hypertension and respiratory failure, when the lungs can’t deliver enough oxygen into the bloodstream.
There is a great unmet clinical need for this disease, as IPF patients have few options to help slow the progression of the disease.
58,000
New cases of IPF are diagnosed each year
2-3
Years is the average prognosis for people with IPF, from the time of diagnosis
Our Research
Active Clinical Trials
recruiting
Complement Mediated DiseaseID: NCT05537025
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of ARO-MMP7 in normal healthy volunteers (NHVs) and in participants with idiopathic pulmonary fibrosis (IPF). The study will initiate with NHVs receiving single ascending doses of ARO-MMP7. Following evaluation of safety and pharmacodynamic (PD) data, participants will receive multiple doses of ARO-MMP7.
Compassionate Use
Learn more about our compassionate use agreement and eligibility criteria for medicines in our pipeline that are currently in clinical development.
